Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             249 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration El mir, S.
 2001
 37 Supplement 3 p. 1053-1060
8 p.
 artikel
2 A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK Ratcliffe, A.
 2001
 37 Supplement 3 p. 4-
1 p.
 artikel
3 Acute and late morbidity in patients with bladder carcinoma treated with ARCON (Accelerated Radiotherapy, Carbogen and Nicotinamide) Hoskin, P.J.
 2001
 37 Supplement 3 p. S222-S223
2 p.
 artikel
4 Adjuvant gemcitabine (GEM) and concurrent irradiation can be safely administered after curative resection of pancreatic adenocarcinoma Demols, A.
 2001
 37 Supplement 3 p. S311-
1 p.
 artikel
5 A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancer Bellmunt, J
 2001
 37 Supplement 3 p. 2212-2215
4 p.
 artikel
6 A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer Einbeigi, Z
 2001
 37 Supplement 3 p. 1904-1909
6 p.
 artikel
7 Against follow-up after curative surgery for colorectal cancer Kronborg, O.
 2001
 37 Supplement 3 p. S364-
1 p.
 artikel
8 A hypothesis about tumour development and the clinical features of hereditary breast cancers Olsson, H.
 2001
 37 Supplement 3 p. 2023-2029
7 p.
 artikel
9 Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line Gemma, A.
 2001
 37 Supplement 3 p. 1554-1561
8 p.
 artikel
10 Altered fractionation in chemo-radiation for bladder cancer Durdux, C.
 2001
 37 Supplement 3 p. S286-
1 p.
 artikel
11 A microcell hybrid based approach identifies human chromosome 3p genes that are silenced following tumor growth, at four distinct regions Kholodnyuk, I.D.
 2001
 37 Supplement 3 p. S277-S278
2 p.
 artikel
12 An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma Astolfi, A.
 2001
 37 Supplement 3 p. 1719-1725
7 p.
 artikel
13 An eight weeks dose-dense versus a 24 weeks sequential adriamcycin/docetaxel combination as preoperative chemotherapy (CHT) in operable breast cancer (T2-3, N0-2,M0) von Minckwitz, G.
 2001
 37 Supplement 3 p. S145-S146
2 p.
 artikel
14 A new approach for the detection of control sites in DNA Mahon, G.A.T.
 2001
 37 Supplement 3 p. S125-
1 p.
 artikel
15 A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells Chang, G.T.G.
 2001
 37 Supplement 3 p. 2129-2134
6 p.
 artikel
16 Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours Aparicio, T
 2001
 37 Supplement 3 p. 1014-1019
6 p.
 artikel
17 A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed Masi, G.
 2001
 37 Supplement 3 p. S294-S295
2 p.
 artikel
18 A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC) Salvador, J.
 2001
 37 Supplement 3 p. S295-S296
2 p.
 artikel
19 A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer Miles, D.W
 2001
 37 Supplement 3 p. 1366-1371
6 p.
 artikel
20 A phase II trial gemcitabine and cisplatin combination chemotherapy in advanced epithelial ovarian cancer with bulky residual disease Shaharyar, L.
 2001
 37 Supplement 3 p. S319-
1 p.
 artikel
21 A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma Llovet, J.M
 2001
 37 Supplement 3 p. 1352-1358
7 p.
 artikel
22 A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer Westermann, A.M
 2001
 37 Supplement 3 p. 1111-1117
7 p.
 artikel
23 Apoptotic effects of thiazolobenzimidazole derivatives on sensitive and multidrug resistant leukaemic cells Grimaudo, S
 2001
 37 Supplement 3 p. 122-130
9 p.
 artikel
24 A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia Rots, M.G.
 2001
 37 Supplement 3 p. 492-498
7 p.
 artikel
25 A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated Veronesi, U
 2001
 37 Supplement 3 p. 2178-2183
6 p.
 artikel
26 A proposal for oncology training at the undergraduate level in Argentina Hunis, A.
 2001
 37 Supplement 3 p. S243-
1 p.
 artikel
27 A randomised, cross over, pilot study to investigate the compliance and tolerance of itraconazole liquid when administered either at room temperature or chilled Grace, S.
 2001
 37 Supplement 3 p. S434-
1 p.
 artikel
28 A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma Gortzak, E
 2001
 37 Supplement 3 p. 1096-1103
8 p.
 artikel
29 Assessing the resource implications of extending routine invitation to breast screening to women aged 65–67 years van der Pol, M
 2001
 37 Supplement 3 p. 1790-1796
7 p.
 artikel
30 Assessing undergraduate palliative care education Mason, S.R.
 2001
 37 Supplement 3 p. S243-S244
2 p.
 artikel
31 A study of 40 patients with nasopharyngeal cancer (stage 1 to 4) treated with radiation therapy using CT simulation with a single isocentre technique and 3 dimensional planning Wahid, M.I.A.
 2001
 37 Supplement 3 p. S216-
1 p.
 artikel
32 A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas Caroli-Bosc, F.X
 2001
 37 Supplement 3 p. 1828-1832
5 p.
 artikel
33 Bad news from the patient's perspective: an analysis of the written narratives of newly diagnosed cancer patients Salander, P.
 2001
 37 Supplement 3 p. S235-
1 p.
 artikel
34 BAX protein expression (BAX-E) correlates with local invasiveness in primary colon cancer (CC) Okech, T.
 2001
 37 Supplement 3 p. S299-
1 p.
 artikel
35 Biochemical responses in cultured cells following exposure to 89SrCl2: potential relevance to the mechanism of action in pain palliation Davis, J
 2001
 37 Supplement 3 p. 2464-2469
6 p.
 artikel
36 Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer–doxorubicin conjugates in nude mice Shiah, J.-G
 2001
 37 Supplement 3 p. 131-139
9 p.
 artikel
37 Bone marrow micrometastases in patients with stage I–II localised prostate cancer Vagunda, V
 2001
 37 Supplement 3 p. 1847-1852
6 p.
 artikel
38 BRCA1 and BRCA2 analysis in breast cancer families from Sardinia: identification of two BRCA2 founder mutations with their clinical and pathological implications Pisano, M.
 2001
 37 Supplement 3 p. S176-
1 p.
 artikel
39 Breast reconstruction, the first step to woman rehabilitation Ferrario, R.
 2001
 37 Supplement 3 p. S427-
1 p.
 artikel
40 CA27.29 Gion, M
 2001
 37 Supplement 3 p. 355-363
9 p.
 artikel
41 CAMPAS: new instrument for measuring symptoms and needs for cancer patients at home: measurement characteristics for pain Rogers, M.
 2001
 37 Supplement 3 p. S430-S431
2 p.
 artikel
42 Cancer nursing competence Fernandez Ortega, P.
 2001
 37 Supplement 3 p. S385-
1 p.
 artikel
43 Cancer patients on the internet. Who surf? Why and where? Kirketerp, A.
 2001
 37 Supplement 3 p. S411-
1 p.
 artikel
44 Cancer surgery in the elderly Hoekstra, Harald J.
 2001
 37 Supplement 3 p. 235-244
10 p.
 artikel
45 Capecitabine named patient program for patients with advanced breast cancer: The UK experience Leonard, R.C.F.
 2001
 37 Supplement 3 p. 28-
1 p.
 artikel
46 Care of the dying patient Borrell, R.
 2001
 37 Supplement 3 p. S407-
1 p.
 artikel
47 Chemopreventive allylthiopyridazine derivatives induce apoptosis in SK-Hep-1 hepatocarcinoma cells through a caspase-3-dependent mechanism Jung, M.-Y
 2001
 37 Supplement 3 p. 2104-2110
7 p.
 artikel
48 Childhood cancer survival in Europe, 1978–1992 Coebergh, J.W.W.
 2001
 37 Supplement 3 p. 671-672
2 p.
 artikel
49 Chromosome 9 aberrations by fluorescence in situ hybridisation in bladder transitional cell carcinoma Eleuteri, P
 2001
 37 Supplement 3 p. 1496-1503
8 p.
 artikel
50 Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial) Costa, S.D.
 2001
 37 Supplement 3 p. S325-
1 p.
 artikel
51 Clinical aspects and management of AIDS-related lymphoma Sparano, J.A
 2001
 37 Supplement 3 p. 1296-1305
10 p.
 artikel
52 Combination chemotherapy of the taxanes and antimetabolites Smorenburg, C.H
 2001
 37 Supplement 3 p. 2310-2323
14 p.
 artikel
53 Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines Tsuruta, Y
 2001
 37 Supplement 3 p. 531-541
11 p.
 artikel
54 Combination of insulin-like growth factor-1 (IGF-1) and amifostine increases the tolerance of the spinal cord to re-irradiation Nieder, C.
 2001
 37 Supplement 3 p. S155-S156
2 p.
 artikel
55 Combination of the TRAIL death ligand with ionizing radiation — rationale and efficacy Belka, C.
 2001
 37 Supplement 3 p. S156-
1 p.
 artikel
56 Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents Adjei, A.
 2001
 37 Supplement 3 p. S216-
1 p.
 artikel
57 Commentary Bleyer, W.A
 2001
 37 Supplement 3 p. 1399-1401
3 p.
 artikel
58 Comparison of biodistribution of two hypoxia markers [18F]fmiso and [18F]fetnim in an experimental mammary carcinoma Gronroos, T.
 2001
 37 Supplement 3 p. S203-
1 p.
 artikel
59 Complementary nursing in Germany with the emphasis on oncological patients — an investigation de Jong, A.
 2001
 37 Supplement 3 p. S406-
1 p.
 artikel
60 Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial Maughan, T.S.
 2001
 37 Supplement 3 p. S271-
1 p.
 artikel
61 Correlation between immunohistochemical and fish analysis for HER-2 in 441 breast carcinomas from multiple hospitals Dowsett, M.
 2001
 37 Supplement 3 p. 3-4
2 p.
 artikel
62 Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease van Agthoven, M
 2001
 37 Supplement 3 p. 1781-1789
9 p.
 artikel
63 CT/MRI image fusion based postplans significantly improve the quality control after prostate seed brachytherapy Kahmann, F.U.
 2001
 37 Supplement 3 p. S220-
1 p.
 artikel
64 Cyclophosphamide dose intesification with filgrastim support in first line cep regimen in advanced ovarian cancer (AOC): a gineco phase III study Ferrero, J.M.
 2001
 37 Supplement 3 p. S318-
1 p.
 artikel
65 Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF Hejna, M
 2001
 37 Supplement 3 p. 1994-2002
9 p.
 artikel
66 Development of a new linac system combined with a self-moving CT and a single common couch Sano, N.
 2001
 37 Supplement 3 p. S212-
1 p.
 artikel
67 Diet and cancer prevention Greenwald, P
 2001
 37 Supplement 3 p. 948-965
18 p.
 artikel
68 Differential expression of transforming growth factors-β1, -β2 and -β3 in human colon carcinoma Bellone, G
 2001
 37 Supplement 3 p. 224-233
10 p.
 artikel
69 Disseminated choriocarcinoma in infancy is curable by chemotherapy and delayed tumour resection Blohm, M.E.G
 2001
 37 Supplement 3 p. 72-78
7 p.
 artikel
70 Does axillary node sampling in addition to sentinel node biopsy provide useful staging information in patients with breast cancer? Hoar, F.J.
 2001
 37 Supplement 3 p. 23-
1 p.
 artikel
71 Does myeloablative BuMel therapy improve survival of poor-risk localized tumor of the Ewing family (ET)? Experience of the French Society of Pediatric Oncology (SFOP) Oberlin, O.
 2001
 37 Supplement 3 p. S337-
1 p.
 artikel
72 Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years Bergeron, C
 2001
 37 Supplement 3 p. 385-391
7 p.
 artikel
73 Dose intensive therapy and myeloablative chemotherapy with haematopoietic stem cell rescue in childhood poor prognosis Ewing's sarcoma Prete, A.
 2001
 37 Supplement 3 p. S265-S266
2 p.
 artikel
74 Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Cervello, M
 2001
 37 Supplement 3 p. 512-519
8 p.
 artikel
75 Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients Cutuli, B.
 2001
 37 Supplement 3 p. 2365-2372
8 p.
 artikel
76 E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo Ozawa, Y
 2001
 37 Supplement 3 p. 2275-2282
8 p.
 artikel
77 Early recurrence and genetic alterations in colorectal cancer Majem, M.
 2001
 37 Supplement 3 p. S257-
1 p.
 artikel
78 Effect of extensive lymph node dissection in surgical treatment of early gastric cancer Chernyavsky, A.A.
 2001
 37 Supplement 3 p. S314-S315
2 p.
 artikel
79 Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation Costa, S.L
 2001
 37 Supplement 3 p. 520-530
11 p.
 artikel
80 Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells Menéndez, J.A.
 2001
 37 Supplement 3 p. 402-413
12 p.
 artikel
81 Effects of the luteinising hormone-releasing hormone (LH-RH) agonist leuprolide on adenylyl cyclase regulation through G-protein coupled receptors in rat ventral prostate Salvador, A
 2001
 37 Supplement 3 p. 641-648
8 p.
 artikel
82 Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC) Amadori, D.
 2001
 37 Supplement 3 p. S195-
1 p.
 artikel
83 Efficacy and safety of three-weekly herceptin with paclitaxel in women with her2-positive metastatic breast cancer: preliminary results of a phase II trial Verma, S.
 2001
 37 Supplement 3 p. S146-
1 p.
 artikel
84 EGFR and cancer prognosis Nicholson, R.I
 2001
 37 Supplement 3 p. 9-15
7 p.
 artikel
85 Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia Saga, T
 2001
 37 Supplement 3 p. 1429-1434
6 p.
 artikel
86 Environmental or hereditary risk of cancer in testicular tumor patients? Gundy, S.
 2001
 37 Supplement 3 p. S223-
1 p.
 artikel
87 Epidemiology in health policy Hakulinen, T.
 2001
 37 Supplement 3 p. S250-
1 p.
 artikel
88 Erratum to ‘Tibolone actions on normal and breast cancer cells’ Eur J Cancer 2000, 36(Suppl. 4), S76–S77 Gompel, A
 2001
 37 Supplement 3 p. 1182-
1 p.
 artikel
89 European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001 2001
 37 Supplement 3 p. 1976-1980
5 p.
 artikel
90 Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients Cheng, K.K.F
 2001
 37 Supplement 3 p. 2056-2063
8 p.
 artikel
91 Expression, function and clinical implications of the estrogen receptor (ER) beta in human lung cancers Omoto, Y.
 2001
 37 Supplement 3 p. S278-
1 p.
 artikel
92 Expression of epidermal growth factor receptor (EGFR) and proliferation markers during fractionated radiotherapy in fadu human squamous cell carcinoma xenografts Eicheler, W.
 2001
 37 Supplement 3 p. S208-
1 p.
 artikel
93 Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells Yi, H.K
 2001
 37 Supplement 3 p. 2257-2263
7 p.
 artikel
94 Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin Witkamp, A.J.
 2001
 37 Supplement 3 p. 979-984
6 p.
 artikel
95 Failure to identify sentinel nodes at operation for screen detrected breast cancers Gill, P.G.
 2001
 37 Supplement 3 p. 19-20
2 p.
 artikel
96 First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study Papakostas, P
 2001
 37 Supplement 3 p. 1833-1838
6 p.
 artikel
97 Fluorescence in situ hybridization (FISH) may accurately identify patients who obtain survival benefit from herceptin plus chemotherapy Mass, R.
 2001
 37 Supplement 3 p. S261-S262
2 p.
 artikel
98 Fractionated Navelbine and Doxorubicin (NA) as front line chemotherapy in metastatic breast cancer (MBC) Carmichael, J.
 2001
 37 Supplement 3 p. S192-
1 p.
 artikel
99 Gemcitabine and cisplatin chemotherapy for patients with metastatic esophageal carcinoma Urba, S.
 2001
 37 Supplement 3 p. S287-
1 p.
 artikel
100 Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens Kosmas, C
 2001
 37 Supplement 3 p. 972-978
7 p.
 artikel
101 Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer Barón, F
 2001
 37 Supplement 3 p. 1381-1384
4 p.
 artikel
102 Generation of HER2-reactive T helper and T killer cells: implementation for T cell therapy Bernhard, Helga
 2001
 37 Supplement 3 p. S6-
1 p.
 artikel
103 Genetic alterations in the pancreatic carcinoma. Prospective study Pantalone, D.
 2001
 37 Supplement 3 p. S116-
1 p.
 artikel
104 Genetic changes of hOGG1 and the activity of oh8Gua glycosylase in colon cancer Park, Y.J
 2001
 37 Supplement 3 p. 340-346
7 p.
 artikel
105 Glut1 expression in T1 and T2 stage colorectal carcinomas Sakashita, M
 2001
 37 Supplement 3 p. 204-209
6 p.
 artikel
106 Hypoxia and its modification Overgaard, Jens
 2001
 37 Supplement 3 p. S137-
1 p.
 artikel
107 ICI 182,780 (‘FASLODEX’) 250 mg monthly Intramuscular (I.M.) injection shows consistent Pharmacokinetic (PK) profiles when given as either 1 × 5 ml or 2 × 2.5 ml injections in postmenopausal women with Advanced Breast Cancer (ABC) Robertson, J.F.R.
 2001
 37 Supplement 3 p. 8-9
2 p.
 artikel
108 Identification of new immunogenic antigens in acute and chronic myeloid leukemias (AML / CML) for the development of vaccines Schmitt, Michael
 2001
 37 Supplement 3 p. S19-
1 p.
 artikel
109 Identifying the concerns of women undergoing chemotherapy treatment for cancer Farrell, C.
 2001
 37 Supplement 3 p. S390-
1 p.
 artikel
110 IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival Katsaros, D.
 2001
 37 Supplement 3 p. 478-485
8 p.
 artikel
111 Immunomagnetic detection and characterisation of circulating tumour cells and cell clusters in patients with colorectal cancer Floro, L.
 2001
 37 Supplement 3 p. S124-S125
2 p.
 artikel
112 Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination Timoshenko, A.V
 2001
 37 Supplement 3 p. 1910-1920
11 p.
 artikel
113 Impact of EU Clinical Trial directive 2001
 37 Supplement 3 p. 1805-1809
5 p.
 artikel
114 Improvement in haemoglobin levels improves health-related quality of life (HRQOL) of anaemic cancer patients Kallich, J.
 2001
 37 Supplement 3 p. S441-S442
2 p.
 artikel
115 Improving fundamental aspects of nursing care through clinical practice benchmarking within a regional cancer centre Good, A.
 2001
 37 Supplement 3 p. S419-
1 p.
 artikel
116 Incidence and prevalence of all cancerous diseases in Italy Verdecchia, A
 2001
 37 Supplement 3 p. 1149-1157
9 p.
 artikel
117 Incidence of lymph node metastases in infiltrating breast cancers of less than 10 mm Sharp, C.M.
 2001
 37 Supplement 3 p. 34-
1 p.
 artikel
118 Increasing specificity of Clostridium mediated protein transfer via radiotherapy: the use of bacterial radio-induced promoters Nuyts, S.
 2001
 37 Supplement 3 p. S274-
1 p.
 artikel
119 Induction of T cell immune response after DNA immunization with human cytochrome P450 CYP1B1 — a potential cancer therapy Ramstedt, Urban
 2001
 37 Supplement 3 p. S27-
1 p.
 artikel
120 Influence of anemia on tumor growth and tumor control — an investigation on advanced cervical cancers Haensgen, G.
 2001
 37 Supplement 3 p. S326-
1 p.
 artikel
121 Informed consent forms: what is the impact? Molin, C.
 2001
 37 Supplement 3 p. S393-
1 p.
 artikel
122 International variations in the surgical management of advanced ovarian cancer between countries participating in scotroc: a large prospective international phase-3 trial Crawford, S.
 2001
 37 Supplement 3 p. S275-S276
2 p.
 artikel
123 Interstitial brachytherapy and external beam radiation in patients with locally advanced carcinomas of the head and neck Stranzl, H.
 2001
 37 Supplement 3 p. S211-S212
2 p.
 artikel
124 Intratumoral treatment 2001
 37 Supplement 3 p. S253-
1 p.
 artikel
125 Invasive lobular carcinoma: Is it still difficult to diagnose? Kurup, V.
 2001
 37 Supplement 3 p. 14-
1 p.
 artikel
126 K167: is it a prognostic index in node negative breast cancer patients? Valcamonico, F.
 2001
 37 Supplement 3 p. S121-
1 p.
 artikel
127 Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters Solomon, B
 2001
 37 Supplement 3 p. 2379-2384
6 p.
 artikel
128 Local fluorouracil releasing microspheres (FU-M) with early radiotherapy (RT) in high grade gliomas (HGG): Preliminary safety assessment of a randomized phase II trial of early RT with or without FU-M in patients with complete surgical resection of HGG Menei, P.
 2001
 37 Supplement 3 p. S342-
1 p.
 artikel
129 Long term central venous access for chemotherapy. Piccline by the radiologist or broviac by the surgeon? Sideris, L.
 2001
 37 Supplement 3 p. S356-
1 p.
 artikel
130 Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin Hengge, U.R
 2001
 37 Supplement 3 p. 878-883
6 p.
 artikel
131 Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment Vehmanen, L
 2001
 37 Supplement 3 p. 2373-2378
6 p.
 artikel
132 Long-term prognosis of gastric cancer in a European country Barchielli, A
 2001
 37 Supplement 3 p. 1674-1680
7 p.
 artikel
133 Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer Försti, A
 2001
 37 Supplement 3 p. 1372-1380
9 p.
 artikel
134 Low CD62L- expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk Graf, M.
 2001
 37 Supplement 3 p. S9-
1 p.
 artikel
135 Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer Yonemura, Y
 2001
 37 Supplement 3 p. 918-923
6 p.
 artikel
136 Malignant bowel obstruction in advanced ovarian cancer: “does that mean I am going to starve to death?” Penfold, R.
 2001
 37 Supplement 3 p. S352-
1 p.
 artikel
137 Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus Wahedna, Y
 2001
 37 Supplement 3 p. 459-462
4 p.
 artikel
138 Measuring the impact of advanced nursing practice in cancer care Craven, O.
 2001
 37 Supplement 3 p. S386-
1 p.
 artikel
139 Modification of doxorubicin-induced cardiotoxicity Chakrabarti, K.B
 2001
 37 Supplement 3 p. 1435-1442
8 p.
 artikel
140 Molecular biology of lung cancer Sozzi, Gabriella
 2001
 37 Supplement 3 p. 63-73
11 p.
 artikel
141 Mouse model of human papillomavirus-associated tumors with downregulated MHC class i expression Smahel, M.
 2001
 37 Supplement 3 p. S230-
1 p.
 artikel
142 MRI enables accurate diagnosis and single stage surgical resection of invasive lobular breast cancers Munot, K.
 2001
 37 Supplement 3 p. 33-
1 p.
 artikel
143 mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas Hagemann, T
 2001
 37 Supplement 3 p. 1839-1846
8 p.
 artikel
144 Natural killer cell activity against the human prostate cancer cell, PC-3: effects of IL-15, GM-CSF and indomethacin Barao, I.
 2001
 37 Supplement 3 p. S229-
1 p.
 artikel
145 Neoadjuvant chemotherapy for osteosarcoma of the extremity Bacci, G
 2001
 37 Supplement 3 p. 2030-2039
10 p.
 artikel
146 Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers Speer, G
 2001
 37 Supplement 3 p. 1463-1468
6 p.
 artikel
147 Oncologists' perceptions and treatment practice variations in the treatment of hormone-refractory prostate cancer (HRPC): a pilot multinational study Amaya, K.
 2001
 37 Supplement 3 p. S145-
1 p.
 artikel
148 Opportunities and burdens for nurse-midwives working in primary health care: Empirical study of the role of the nurse-midwife in population-based cervical cancer screening in urban Sweden Widmark, C.
 2001
 37 Supplement 3 p. S402-
1 p.
 artikel
149 Osteoradionecrosis of pelvic bones — a single institution experience Feltl, D.
 2001
 37 Supplement 3 p. S199-S200
2 p.
 artikel
150 Outline of proposed topic of lecture: The epidemiology of adenocarcinoma of the esophagus Lagergren, J.
 2001
 37 Supplement 3 p. S246-
1 p.
 artikel
151 Overexpression of angiogenic growth factors, VEGF, PDGF, and bFGF in head and neck squamous cell carcinoma in the betel quid chewing prevalent area Chang, J.T.
 2001
 37 Supplement 3 p. S113-
1 p.
 artikel
152 Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer Kristiansen, G
 2001
 37 Supplement 3 p. 1089-1095
7 p.
 artikel
153 Oxaliplatin (L-OHP) and irinotecan (CPT-11) with 6s-leucovorin (IFA)-modulated 5-fluorouracil (FU) i.v. bolus every 2 weeks: a dose-finding study in patients (pts) with gastrointestinal malignancies Comella, P.
 2001
 37 Supplement 3 p. S302-
1 p.
 artikel
154 Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study De Lena, M.
 2001
 37 Supplement 3 p. 364-368
5 p.
 artikel
155 Pancreatic cancer surgery - The chance to be cured: Who benefits? Beger, H.G.
 2001
 37 Supplement 3 p. S253-
1 p.
 artikel
156 Patients facing alopecia Branco, A.
 2001
 37 Supplement 3 p. S437-
1 p.
 artikel
157 Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy Bacci, G
 2001
 37 Supplement 3 p. 32-38
7 p.
 artikel
158 PEG-intron is effective therapy for essential thrombocythemia Giles, F.
 2001
 37 Supplement 3 p. S227-
1 p.
 artikel
159 Pharmaco-genomics in breast cancer 2001
 37 Supplement 3 p. S134-
1 p.
 artikel
160 Phase II study of capecitabine (C) in patients with metastatic squamous cell carcinoma of the cervix (SCCC) Moiseyenko, V.M.
 2001
 37 Supplement 3 p. S329-
1 p.
 artikel
161 Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study Wagenaar, H.C.
 2001
 37 Supplement 3 p. 1624-1628
5 p.
 artikel
162 Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck Harrington, K.J
 2001
 37 Supplement 3 p. 2015-2022
8 p.
 artikel
163 Phase II trial of HLA-b7 plasmid dna/lipid (allovectin-7®) immunotherapy in patients with metastatic melanoma Gutheil, J.
 2001
 37 Supplement 3 p. S160-
1 p.
 artikel
164 Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report Coudert, B
 2001
 37 Supplement 3 p. 2194-2198
5 p.
 artikel
165 Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer Alonso, V
 2001
 37 Supplement 3 p. 2385-2391
7 p.
 artikel
166 Population-based survival from colorectal cancer in Mumbai, (Bombay) India Yeole, B.B
 2001
 37 Supplement 3 p. 1402-1408
7 p.
 artikel
167 Positron emission tomography (PET) image registration into 3-dimensional radiotherapy treatment planning for lung cancer alters computed tomography (CT)-defined tumor and treatment volumes Russo, S.
 2001
 37 Supplement 3 p. S258-S259
2 p.
 artikel
168 Power doppler with use of contrast in the differentiation of ovarian tumors Blanco, E.C.
 2001
 37 Supplement 3 p. S322-
1 p.
 artikel
169 Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy Coiffier, B
 2001
 37 Supplement 3 p. 1617-1623
7 p.
 artikel
170 Preoperative chemoradiation with raltitrexed (‘tomudex’) alone or in combination with oxaliplatin in T3 rectal carcinoma: review of four phase I–II studies Valentini, V.
 2001
 37 Supplement 3 p. S291-
1 p.
 artikel
171 Preoperative chemoradiation with raltitrexed (‘Tomudex’) for T2/N+ and T3/N+ rectal cancers Valentini, V.
 2001
 37 Supplement 3 p. 2050-2055
6 p.
 artikel
172 Preoperative chemotherapy for operable breast cancer: role of pathological features in predicting clinical and pathological response Orlando, L.
 2001
 37 Supplement 3 p. S179-S180
2 p.
 artikel
173 Primary and secondary prevention in the reduction of cancer morbidity and mortality Adami, H.-O.
 2001
 37 Supplement 3 p. 118-127
10 p.
 artikel
174 Primary cutaneous melanoma in hidden sites is associated with thicker tumours — a study of 829 patients Nagore, E
 2001
 37 Supplement 3 p. 79-82
4 p.
 artikel
175 Primary squamous cell carcinoma of the vagina: Experience at the Gustave-Roussy Institute de Crevoisier, R.
 2001
 37 Supplement 3 p. S328-S329
2 p.
 artikel
176 Privacy: a nursing key concept Maia, H.
 2001
 37 Supplement 3 p. S423-
1 p.
 artikel
177 Prognostic factors of breast cancer patients with 1 to 3 lymph node metastases after adjuvant chemotherapy Lin, Y.
 2001
 37 Supplement 3 p. S183-
1 p.
 artikel
178 Prognostic features and survival of hepatocellular carcinoma in Italy Lerose, R
 2001
 37 Supplement 3 p. 239-245
7 p.
 artikel
179 Prospective randomised study comparing radio-guided surgery (ROLL) to wire-guidance for occult breast lesions localisation Rampaul, R.S.
 2001
 37 Supplement 3 p. 2-3
2 p.
 artikel
180 Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus Wobbes, Th.
 2001
 37 Supplement 3 p. 470-477
8 p.
 artikel
181 Psychological reactions among women with high risk of breast cancer considering prophylactic mastectomy Brandberg, Y.
 2001
 37 Supplement 3 p. S231-
1 p.
 artikel
182 Quality assurance in the diagnosis of breast disease Perry, N.M.
 2001
 37 Supplement 3 p. 159-172
14 p.
 artikel
183 Quality of sexual life in women with breast cancer and their spouses Heras, P.
 2001
 37 Supplement 3 p. S350-
1 p.
 artikel
184 Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Zouhair, A
 2001
 37 Supplement 3 p. 198-203
6 p.
 artikel
185 Radiotherapy for age-related macula disease: a longitudinal single-arm study Gripp, S.
 2001
 37 Supplement 3 p. S199-
1 p.
 artikel
186 Raltitrexed combined with 5-fluorouracil continuous infusion: a phase I/II dose-escalation trial in advanced solid tumors Massuti, B.
 2001
 37 Supplement 3 p. S310-
1 p.
 artikel
187 Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis Tsukada, H.
 2001
 37 Supplement 3 p. 2398-2404
7 p.
 artikel
188 Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma Judson, I
 2001
 37 Supplement 3 p. 870-877
8 p.
 artikel
189 Randomised trial with or without amifostin to reduce neurotoxic side effects under chemotherapy with oxaliplatin (L-OHP), FA/-FU (Folfox 3) Rudolph, S.
 2001
 37 Supplement 3 p. S362-
1 p.
 artikel
190 Realising the benefits of multiprofessional collaboration in research Fitch, M.I.
 2001
 37 Supplement 3 p. S398-
1 p.
 artikel
191 Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2 Correale, P
 2001
 37 Supplement 3 p. 892-902
11 p.
 artikel
192 Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases Nieder, C.
 2001
 37 Supplement 3 p. S341-
1 p.
 artikel
193 Reduced utilisation of specialist care among elderly cancer patients Johansson, B
 2001
 37 Supplement 3 p. 2161-2168
8 p.
 artikel
194 Referees — 2001 2001
 37 Supplement 3 p. 2500-2501
2 p.
 artikel
195 Rehabilitation in the Netherlands: Herstel & Balans, a promising program for cancer patients Gijsen, B.C.M.
 2001
 37 Supplement 3 p. S397-
1 p.
 artikel
196 Replacing axillary dissection by irradiation in cNO postmenopausal women with breast cancer: long term results in patients treated between 1986 and 1993 Albrecht, M.
 2001
 37 Supplement 3 p. S184-
1 p.
 artikel
197 Results of a phase II HPV vaccine trial with life recombinant vaccinia virus TA-HPV™ Kaufmann, AM
 2001
 37 Supplement 3 p. S20-
1 p.
 artikel
198 Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer Namer, M
 2001
 37 Supplement 3 p. 1132-1140
9 p.
 artikel
199 Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice Liu, D.
 2001
 37 Supplement 3 p. 268-280
13 p.
 artikel
200 Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts Schuldes, H
 2001
 37 Supplement 3 p. 660-667
8 p.
 artikel
201 Ribozyme targeting of HER-2 inhibits pancreatic cancer cell growth in vivo Thybusch-Bernhardt, A.
 2001
 37 Supplement 3 p. 1688-1694
7 p.
 artikel
202 Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer Ohe, Y
 2001
 37 Supplement 3 p. 54-63
10 p.
 artikel
203 Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer Ververs, J.M.M.A
 2001
 37 Supplement 3 p. 991-999
9 p.
 artikel
204 Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer Boucaud, M.
 2001
 37 Supplement 3 p. 2357-2364
8 p.
 artikel
205 Secondary malignancies in patients treated for sarcoma Bielack, S.
 2001
 37 Supplement 3 p. S140-S141
2 p.
 artikel
206 Selective cytotoxicity of a diphtheria toxin-interleukin-3 fusion protein on acute myeloid leukemia stem cells Feuring-Buske, M.
 2001
 37 Supplement 3 p. S12-
1 p.
 artikel
207 Sentinel node biopsy in breast cancer: are there differences according to the time of radioisotope injection? Fougo, J.
 2001
 37 Supplement 3 p. S188-
1 p.
 artikel
208 Serum levels and tumor expression of HER-2 in colorectal cancer (CRC) — a prospective analysis Behnecke, M.
 2001
 37 Supplement 3 p. S306-
1 p.
 artikel
209 Short- and long-term anxiety and depression in women recalled after breast cancer screening Lampic, C
 2001
 37 Supplement 3 p. 463-469
7 p.
 artikel
210 Simultaneous radio-chemotherapy of malignant gliomas with topotecan Gross, M.W.
 2001
 37 Supplement 3 p. S345-
1 p.
 artikel
211 Skin protection by use of sucralfate cream during external beam radiotherapy for breast cancer: a prospective double blind randomized phase II study Gutierrez, C.
 2001
 37 Supplement 3 p. S360-
1 p.
 artikel
212 Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer de Graeff, A
 2001
 37 Supplement 3 p. 332-339
8 p.
 artikel
213 Soluble plasma P-selectin is elevated in patients with advanced carcinoma McAllister, I.
 2001
 37 Supplement 3 p. S129-
1 p.
 artikel
214 Staff support groups in an oncology hospital Anagnostopoulos, F.
 2001
 37 Supplement 3 p. S419-S420
2 p.
 artikel
215 State of the art in systemic treatment of lung cancer Giaccone, Giuseppe
 2001
 37 Supplement 3 p. 99-114
16 p.
 artikel
216 Superposed images of FDG-PET and CT in a commercially available 3-dimensional radiation treatment planning system in patients with non small cell lung cancer Paulsen, F.
 2001
 37 Supplement 3 p. S274-
1 p.
 artikel
217 Survival of children with thyroid cancer in Europe 1978–1989 Storm, H.H
 2001
 37 Supplement 3 p. 775-779
5 p.
 artikel
218 Target volume definition in non-small cell lung cancer using 3-dimensional image registration of pre- and post-chemotherapy CT scans van de Vaart, P.
 2001
 37 Supplement 3 p. S259-
1 p.
 artikel
219 Testosterone, an hormonal marker for breast cancer in postmenopausal women(PM): preliminary results of a case-control study in Montreal Latreille, J.
 2001
 37 Supplement 3 p. S167-S168
2 p.
 artikel
220 The aetiology of second soft tissue sarcomas occurring after childhood cancer in Britain Jenkinson, H.C.
 2001
 37 Supplement 3 p. S333-
1 p.
 artikel
221 The ALMANAC trial — early results from the audit phase Clarke, D.
 2001
 37 Supplement 3 p. 18-19
2 p.
 artikel
222 The ATAC (Arimidex, Tamoxifen, alone or in combination) trial in post-menopausal patients with operable breast cancer Tobias, J.
 2001
 37 Supplement 3 p. S171-
1 p.
 artikel
223 The benefit of individualized custom bolus in the postmastectomy radiation therapy: Numerical analysis with 3-D treatment planning Suh, C.
 2001
 37 Supplement 3 p. S188-S189
2 p.
 artikel
224 The effect of prednisolone following whole brain irrdiation on blood-brain barrier of the mouse - In the view of acute change Kim, I.A.
 2001
 37 Supplement 3 p. S359-S360
2 p.
 artikel
225 The history of breast cysts is not associated with the diagnosis of breast cancer Chetty, U.
 2001
 37 Supplement 3 p. 39-
1 p.
 artikel
226 The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy Jobsen, J.J
 2001
 37 Supplement 3 p. 1820-1827
8 p.
 artikel
227 The luck of the draw — who gets admitted to palliative care? Goodman, M.
 2001
 37 Supplement 3 p. S349-
1 p.
 artikel
228 The needs of family members of cancer patients when they are in hospital Martins, C.
 2001
 37 Supplement 3 p. S426-
1 p.
 artikel
229 The needs of the post-basic course development in cancer-related fatigue management Laze, I.
 2001
 37 Supplement 3 p. S415-
1 p.
 artikel
230 The prognostic value of histological subtype and tumor volume in localized unilateral nephroblastoma Graf, N.
 2001
 37 Supplement 3 p. S282-
1 p.
 artikel
231 The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy Magné, N
 2001
 37 Supplement 3 p. 2169-2177
9 p.
 artikel
232 The role of complementary and alternative medicine in cancer Ernst, E.
 2001
 37 Supplement 3 p. S164-
1 p.
 artikel
233 The role of serum cystatin c and TC-99M MAG-3 renal scintigraphy for predicting cisplatin induced nephrotoxicity in cancer patients Gunel, N.
 2001
 37 Supplement 3 p. S359-
1 p.
 artikel
234 The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer Mizutani, Y.
 2001
 37 Supplement 3 p. 569-575
7 p.
 artikel
235 The UK view point 2001
 37 Supplement 3 p. S164-
1 p.
 artikel
236 The use of anti-CD3/CD28-dynabeads to restimulate human antigen specific T cells or expand naïve T cells Rasmussen, Anne-Marie
 2001
 37 Supplement 3 p. S13-
1 p.
 artikel
237 Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo Fukushima, M
 2001
 37 Supplement 3 p. 1681-1687
7 p.
 artikel
238 Thyroid cancer after irradiation Schlumberger, Martin
 2001
 37 Supplement 3 p. S133-
1 p.
 artikel
239 T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell–cell contacts Demeure, C.E
 2001
 37 Supplement 3 p. 1709-1718
10 p.
 artikel
240 Treatment of hepatocellular carcinoma in a rat model using electrochemotherapy Jaroszeski, M.J
 2001
 37 Supplement 3 p. 422-430
9 p.
 artikel
241 UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial Ravaud, A.
 2001
 37 Supplement 3 p. 1642-1647
6 p.
 artikel
242 Upstaging of breast cancer patients with PT1 tumours by detection of micrometastasis in sentinel lymph node biopsy (SLND) Langer, I.
 2001
 37 Supplement 3 p. S180-
1 p.
 artikel
243 Using a collaborative approach to measure patient satisfaction of supportive care throughout the breast cancer journey Horsfield, S.
 2001
 37 Supplement 3 p. S438-
1 p.
 artikel
244 Veno-occlusive disease with multi-organ involvement following actinomycin-D D'Antiga, L
 2001
 37 Supplement 3 p. 1141-1148
8 p.
 artikel
245 Weekly cisplatin - epirubicin - paclitaxel (PET) with G-CSF support vs. triweekly epirubicin-paclitaxel (ET) in advanced breast cancer (ABC). A SICOG phase III trial Frasci, G.
 2001
 37 Supplement 3 p. S151-S152
2 p.
 artikel
246 What is the patient and sitter opinion about cancer diagnosis disclosure? A study from the Middle East Abdelwarith, A.
 2001
 37 Supplement 3 p. S239-
1 p.
 artikel
247 Will clinical oncology really change? 2001
 37 Supplement 3 p. S369-
1 p.
 artikel
248 Willingness-to-pay for colorectal cancer screening Frew, E
 2001
 37 Supplement 3 p. 1746-1751
6 p.
 artikel
249 ZD0473 phase II monotherapy trial in second-line ovarian cancer Gore, M.
 2001
 37 Supplement 3 p. S261-
1 p.
 artikel
                             249 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland